I-BET151 (GSK1210151A)

Catalog No.S2780

I-BET151 (GSK1210151A) Chemical Structure

Molecular Weight(MW): 415.44

I-BET151 (GSK1210151A) is a novel selective BET inhibitor for BRD2, BRD3 and BRD4 with IC50 of 0.5 μM, 0.25 μM, and 0.79 μM in cell-free assays, respectively.

Size Price Stock Quantity  
USD 170 In stock
USD 270 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • OVTOKO and OVCA420 cells were treated with DMSO, JQ1 (1 μM) or I-BET151 (1 μM). Cell lysates were immunoblotted with indicated antibodies.

    Theranostics, 2016, 6(2):219-30.. I-BET151 (GSK1210151A) purchased from Selleck.

    B. Western blot analysis of pERK and ERK in cells treated with JQ1 or I-BET151.

    Oncotarget, 2016, 7(3):2545-54. I-BET151 (GSK1210151A) purchased from Selleck.

  • C57BL/6 mice were primed with Ad26 (109 vp) and boosted with Ad5 (109 vp) in combination with RMD, IBET151, RMD+IBET151, or PBS/DMSO. (B) Frequency of Gag-specific IFN-γ+ CD8+ T cells in the spleen.

    J Immunol, 2018, 201(9):2744-2752. I-BET151 (GSK1210151A) purchased from Selleck.

Purity & Quality Control

Choose Selective Epigenetic Reader Domain Inhibitors

Biological Activity

Description I-BET151 (GSK1210151A) is a novel selective BET inhibitor for BRD2, BRD3 and BRD4 with IC50 of 0.5 μM, 0.25 μM, and 0.79 μM in cell-free assays, respectively.
Features Optimized to retain excellent BET target potency and selectivity while enhancing the in vivo pharmacokinetics and terminal half-life to enable prolonged in vivo studies.
Targets
BRD3 [1]
(Cell-free assay)
BRD2 [1]
(Cell-free assay)
BRD4 [1]
(Cell-free assay)
0.25 μM 0.5 μM 0.79 μM
In vitro

I-BET151 exhibits potent selectivity over an extensive range of diverse protein types such as COX-2, P450, Aurora B, GSK3β, PI3K-γ, GPCR, ion channels, and transporters. Similar to I-BET762 (GSK525762A), I-BET151 displays potent binding affinity to BRD2, BRD3 and BRD4 with KD of 0.02-0.1 μM, and significantly inhibits lipopolysaccharide-stimulated IL-6 cytokine production in human peripheral blood mononuclear cells (PBMC) and whole blood (WB) as well as rat WB with IC50 of 0.16 μM, 1.26 μM, and 1.26 μM, respectively. I-BET151 (0.5 or 5 μM) inhibits the binding of BETs (BRD2, BRD3, BRD4, and BRD9) but not the binding of 23 other bromodomain proteins in HL60 nuclear extract to acetylated histone peptides. I-BET151 has potent efficacy against cell lines harboring different MLL-fusions such as MV4;11, RS4;11, MOLM13, and NOMO1 cells with IC50 of 15-192 nM. Consistently, I-BET151 completely ablates the colony-forming potential of MLL-fusion-driven leukaemias (MOLM13) but not leukaemias driven by tyrosine kinase activation (K562). I-BET151 also displays potent efficacy in both liquid culture and clonogenic assays using primary murine progenitors transformed with either MLL-ENL or MLL-AF9. I-BET151 treatment significantly induces apoptosis and prominent G0/G1 arrest in MLL-fusion cell lines driven by distinct MLL fusions (MOLM13 and MV4;11 containing MLL-AF9 and MLL-AF4, respectively) but not the K562 cells, probably due to the inhibition of transcription of BCL2, C-MYC and CDK6 by blocking the recruitment of BRD3/4, PAFc and SEC components into transcriptional start site (TSS). [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV4;11 MWjjfZRwfG:6aXPpeJkh[XO|YYm= M2TLSJ4yODBizszN M4H0WGROW09? MUjJR|UxRTJ4IH7N M4XuU|IyQTZ2M{Sw
RS4;11 MXnjfZRwfG:6aXPpeJkh[XO|YYm= NFvGSmh,OTByIN88US=> MYrEUXNQ MX\JR|UxRTF7MjDuUS=> NUG0eVRjOjF7NkSzOFA>
MOLM13 NXjRT4Rq[3m2b4TvfIlkcXS7IHHzd4F6 M3nycZ4yODBizszN Mk\ESG1UVw>? M4fkVmlEPTB;MUKwJI5O M4\p[|IyQTZ2M{Sw
NOMO1 MWTjfZRwfG:6aXPpeJkh[XO|YYm= MoLGglExOCEQvF2= MV\EUXNQ MnLZTWM2OD1zNTDuUS=> NVzKb3FSOjF7NkSzOFA>
HEL MnfRZ5l1d3SxeHnjbZR6KGG|c3H5 NGS3NmN,OTByIN88US=> MVjEUXNQ NXGy[HBQUUN3ME2xJO69VQ>? MX[yNVk3PDN2MB?=
K562 NHr4WGtkgXSxdH;4bYNqfHliYYPzZZk> MU\+NVAxKM7:TR?= NGTneW1FVVOR NXryb5ExUUN3ME6xNFAh|ryP MV2yNVk3PDN2MB?=
MEG01 NH;5ZVNkgXSxdH;4bYNqfHliYYPzZZk> NFfpXnB,OTByIN88US=> NYnHNHhUTE2VTx?= NUjlb2Z6UUN3ME2yOUDPxE1? NYf5NYFsOjF7NkSzOFA>
HL60 M17RfoN6fG:2b4jpZ4l1gSCjc4PhfS=> MmDJglExOCEQvF2= MkjvSG1UVw>? Mn3WTWM2OD16OUCgcm0> MUeyNVk3PDN2MB?=
MV4;11 MlvSRZBweHSxc3nzJIF{e2G7 MoXpglExOCEQvF2= NWrkbXo2TE2VTx?= NUm4bGJlcW6mdXPld{BieG:ydH;zbZM> NWfDfppQOjF7NkSzOFA>
MOLM13 MYnBdI9xfG:|aYOgZZN{[Xl? NFLJOIt,OTByIN88US=> M3;oR2ROW09? MmfWbY5lfWOnczDhdI9xfG:|aYO= MViyNVk3PDN2MB?=
MV4;11 MV3GeY5kfGmxbjDhd5NigQ>? MmrtSG1UVw>? MoLu[IVkemWjc3XzJJRp\SC{ZXPyeYl1dWWwdDDv[kBDWkR|L{SgZY5lKGmvcHHpdoVlKHKnY4L1bZRu\W62IH;mJGNFUzliYX7kJHBCTjFidH:geIhmKHS{YX7zZ5JqeHSrb37hcEB{fGG{dDDzbZRm Mn63NlE6PjR|NEC=
PBMC Ml;aSpVv[3Srb36gZZN{[Xl? MXvEUXNQ NXj5W|FmcW6qaXLpeJMhUUxvNjD3bZRpKHCLQ{WwJI9nKDZwNx?= M{XNOVIzPDN5MUG1
A2 MUPGeY5kfGmxbjDhd5NigQ>? NIXrOZB,OTBizszN MorQSG1UVw>? M133d5Jm[WO2aY\heIV{KGyjdHXueEBJUVZvMR?= MVSyN|I2PTJzOB?=
A72 NFLBS4RHfW6ldHnvckBie3OjeR?= M1LVXJ4yOCEQvF2= NEfpNnJFVVOR MWny[YFkfGm4YYTld{Bt[XSnboSgTGlXNTF? NFTmT3AzOzJ3NUKxPC=>
BC1 Ml\iS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MnjqglEh|ryP NWL3NoxOTE2VTx?= MlTxTWM2OD1{MkCgcm0> NYO3fXZWOjN5OUK0OFg>
BC3 M2DkUGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NFHaZnJ,OSEQvF2= NVLubWhHTE2VTx?= NH;2PZpKSzVyPUS2NEBvVQ>? M2\YW|I{Pzl{NES4
BCBL1 NEfEfm5Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M4LQfp4yKM7:TR?= M{P0e2ROW09? M4HpfmlEPTB;M{OwJI5O MmTONlM4QTJ2NEi=
BJAB NWDRPVU4T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M1nlPZ4yKM7:TR?= NUnqUnNMTE2VTx?= M{DVTmlEPTB;OUewJI5O NGDMfVkzOzd7MkS0PC=>
Namalwa MoXSS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MofpglEh|ryP M2fEfmROW09? MUPJR|UxRTl5MDDuUS=> M4XLPVI{Pzl{NES4
Jurkat MnLhS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NIHnXI1,OSEQvF2= MU\EUXNQ NIr5enlKSzVyPUGyNlAhdk1? NIH5fWgzOzd7MkS0PC=>
MM1S M3XyZ2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MkTWglEh|ryP NIrSOY5FVVOR NFPGSINKSzVyPUe2NEBvVQ>? M1rjd|I{Pzl{NES4
U266 NHLGWYtIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NULaVGdYhjFizszN Mlm0SG1UVw>? NVTLcVJ{UUN3ME25OVAhdk1? M33yZ|I{Pzl{NES4
UM-PEL-1 MVPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M4CwWp4yKM7:TR?= M2C2PGROW09? NG\Ec2xKSzVyPUKxNEBvVQ>? MYqyN|c6OjR2OB?=
UM-PEL-3 NWnhfoxUT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M17xb54yKM7:TR?= MkXxSG1UVw>? MmSyTWM2OD1zOECgcm0> NV7CTph7OjN5OUK0OFg>
BC1 NWPISok2TnWwY4Tpc44h[XO|YYm= MXi1NFAhdk1? NVO4T49vTE2VTx?= M1zFTolv\HWlZYOgZ4VtdC2leXPs[UBienKnc4S= NWDTfJJKOjN5OUK0OFg>
BC3 MkfUSpVv[3Srb36gZZN{[Xl? MnP1OVAxKG6P MYnEUXNQ M1zNeIlv\HWlZYOgZ4VtdC2leXPs[UBienKnc4S= NWLXXHlCOjN5OUK0OFg>
BC1 MX;GeY5kfGmxbjDhd5NigQ>? NHXE[lc5ODBibl2= NInqPIhFVVOR MXfy[YR2[2W|IHOtUZlkKHC{b4TlbY4hdGW4ZXzz NWPmd|J6OjN5OUK0OFg>
BC3 NUnhfFF3TnWwY4Tpc44h[XO|YYm= NFfTU|I5ODBibl2= M3fDcWROW09? M33ldJJm\HWlZYOgZ{1OgWNicILveIVqdiCuZY\lcJM> MljzNlM4QTJ2NEi=
H929 MnXmSpVv[3Srb36gZZN{[Xl? M33Y[p4yKM7:TR?= MnXrSG1UVw>? MUjpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2 MlnaNlQ{OzV2OUm=
KMS12PE NYjxfnRETnWwY4Tpc44h[XO|YYm= M1yyUJ4yKM7:TR?= NXTm[2lSTE2VTx?= MXLpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2 MY[yOFM{PTR7OR?=
KMS12BM NXnvZlZRTnWwY4Tpc44h[XO|YYm= MVf+NUDPxE1? NWHPc3JUTE2VTx?= NGjaVllqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0 MXOyOFM{PTR7OR?=
KMS18 MkjqSpVv[3Srb36gZZN{[Xl? M2ixb54yKM7:TR?= NIO1[GVFVVOR MnjxbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dB?= MlrLNlQ{OzV2OUm=
KMS11 MXzGeY5kfGmxbjDhd5NigQ>? MlLnglEh|ryP NFHzdYxFVVOR NEHrdYFqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0 NGDHWmkzPDN|NUS5PS=>
RPMI8226 Mle3SpVv[3Srb36gZZN{[Xl? MVL+NUDPxE1? MoS1SG1UVw>? NUDKTHNTcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeC=> M3vad|I1OzN3NEm5
H929 NVPzfml7SXCxcITvd4l{KGG|c3H5 NHKwfYl,OSEQvF2= MWnEUXNQ Ml;CbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NVLFTFFkOjR|M{W0PVk>
KMS12PE MX;BdI9xfG:|aYOgZZN{[Xl? M3fvU54yKM7:TR?= NGr5VZRFVVOR MmG1bY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MXSyOFM{PTR7OR?=
KMS12BM MmCxRZBweHSxc3nzJIF{e2G7 MlfGglEh|ryP M3uySGROW09? NVPadJRDcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NULXV3hkOjR|M{W0PVk>
KMS18 M4nv[GFxd3C2b4Ppd{Bie3OjeR?= MYr+NUDPxE1? NH3WUlNFVVOR MXfpcoR2[2W|IHPlcIwh[XCxcITvd4l{ NIm2RlIzPDN|NUS5PS=>
KMS11 NXPERpB{SXCxcITvd4l{KGG|c3H5 MX;+NUDPxE1? NXzve5dRTE2VTx?= NIDBRoNqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NHfKfnkzPDN|NUS5PS=>
RPMI8226 NIHMOGNCeG:ydH;zbZMh[XO|YYm= NF7YRnR,OSEQvF2= M1S4dmROW09? NWmxbHdVcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NI\NZlIzPDN|NUS5PS=>
U87MG NIro[ZlHfW6ldHnvckBie3OjeR?= MV3+NVAh|ryP NFixdHZFVVOR M1LoWpJm\HWlZYOgWVg4VUdiY3XscJVt[XJiQWTQJJdqfGhiSVO1NEBw\iBzLkC1JO69VQ>? MmDHNlQ1QTZ|OEG=
A172 MXrGeY5kfGmxbjDhd5NigQ>? M3;KXJ4yOCEQvF2= NHHJOpFFVVOR NYLBSFI3emWmdXPld{Bk\WyudXzhdkBCXFBid3n0bEBKSzVyIH;mJFEvOjhizszN NXPJVmk3OjR2OU[zPFE>
SW1783 NEfDblhHfW6ldHnvckBie3OjeR?= M3i2fp4yOCEQvF2= NG\acYVFVVOR MXTy[YR2[2W|IHPlcIx2dGG{IFHUVEB4cXSqIFnDOVAhd2ZiMj62PEDPxE1? NY\qd|FtOjR2OU[zPFE>
U87MG MYnGeY5kfGmxbjDhd5NigQ>? NYOwR2QzhjFyIN88US=> MWnEUXNQ MlexbY5kemWjc3XzJJBzd3CxcoTpc44hd2ZiY3XscJMhcW5idHjlJGcyN1NidILhcpNqfGmxbh?= M3nldlI1PDl4M{ix
RAW267.4 Mki0SpVv[3Srb36gZZN{[Xl? M3\UcFEh|ryP Ml62SG1UVw>? M{XEcpJm\HWlZYOgTWwuPiCycn;keYN1cW:wIHnu[JVk\WRiYomgUHBU NUi4SXp7OjR6NUmwNFg>
RAW267.4 M1\C[GZ2dmO2aX;uJIF{e2G7 Ml3rNUDPxE1? NWmw[JF4TE2VTx?= MXTy[YR2[2W|IITo[UBie3OxY3nheIlwdiCkZYT3[YVvKEKURESgZY5lKGGlZYT5cIF1\WRicE[1 NYfWXVh4OjR6NUmwNFg>
Me007 NX3YOoNnT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NIW4Nol,OTByIN88US=> MV7EUXNQ MWrpcohq[mm2czD0bIUh\3Kxd4To MnPzNlQ6ODZzM{e=
SK-Mel-28 NHvNZ5ZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MXX+NVAxKM7:TR?= NUe2U5B6TE2VTx?= NEnqPHVqdmirYnn0d{B1cGViZ4Lve5Rp M1v3SVI1QTB4MUO3
Mel-RMU NHTsPHpIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MlfvglExOCEQvF2= NUPjUGVSTE2VTx?= NFW0bGxqdmirYnn0d{B1cGViZ4Lve5Rp NFnuN|gzPDlyNkGzOy=>
Mel-JD MkjJS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MYP+NVAxKM7:TR?= M1LmUWROW09? NIPOfY5qdmirYnn0d{B1cGViZ4Lve5Rp NWP6OotMOjR7ME[xN|c>
Mel-RM NE[zUJZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NIPoUVB,OTByIN88US=> NWHkZ4ZkTE2VTx?= NH;vZo5qdmirYnn0d{B1cGViZ4Lve5Rp M1fuPFI1QTB4MUO3
Me007 NFrSVXdCeG:ydH;zbZMh[XO|YYm= MUn+NVAxKM7:TR?= NG\WZmhFVVOR MX;pcoR2[2W|IHHwc5B1d3Orcx?= MWeyOFkxPjF|Nx?=
SK-Mel-28 NVPpUWdWSXCxcITvd4l{KGG|c3H5 MWL+NVAxKM7:TR?= MVzEUXNQ NGD5cXNqdmS3Y3XzJIFxd3C2b4Ppdy=> NEftbVEzPDlyNkGzOy=>
Mel-RMU Mkj1RZBweHSxc3nzJIF{e2G7 M3r4VZ4yODBizszN M1LrS2ROW09? MWrpcoR2[2W|IHHwc5B1d3Orcx?= M{LpNVI1QTB4MUO3
Mel-JD MUTBdI9xfG:|aYOgZZN{[Xl? Mli5glExOCEQvF2= M3H4VmROW09? NWi3PVE1cW6mdXPld{BieG:ydH;zbZM> MXqyOFkxPjF|Nx?=
Mel-RM MYfBdI9xfG:|aYOgZZN{[Xl? MlLtglExOCEQvF2= NFzLVZRFVVOR MVnpcoR2[2W|IHHwc5B1d3Orcx?= M1HmcVI1QTB4MUO3
Me007 M2nPT2Z2dmO2aX;uJIF{e2G7 NHPUUI0yOCEQvF2= M33BfmROW09? MoXXbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDifUB2eHKnZ4XsZZRqd25ib3[gdFIy MV[yOFkxPjF|Nx?=
SK-Mel-28 NHjKT5ZHfW6ldHnvckBie3OjeR?= MmGyNVAh|ryP MVPEUXNQ MVLpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2IHL5JJVxemWpdXzheIlwdiCxZjDwNlE> NWfmbIhHOjR7ME[xN|c>
Mel-RMU NU\TZVRNTnWwY4Tpc44h[XO|YYm= M4LYdVExKM7:TR?= NGrqVFlFVVOR M3LNZYlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgZpkhfXC{ZXf1cIF1cW:wIH;mJJAzOQ>? M4S3elI1QTB4MUO3
Mel-JD NHTCcmRHfW6ldHnvckBie3OjeR?= MV:xNEDPxE1? Mn3kSG1UVw>? MWfpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2IHL5JJVxemWpdXzheIlwdiCxZjDwNlE> NVe5OmtKOjR7ME[xN|c>
Mel-RM M37nXmZ2dmO2aX;uJIF{e2G7 NV3LSJRwOTBizszN NW\JW5lSTE2VTx?= NGex[3ZqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIJ6KHWycnXneYxifGmxbjDv[kBxOjF? NELhNW0zPDlyNkGzOy=>
Me007 NFq4bnVHfW6ldHnvckBie3OjeR?= NIDlcHkyOCEQvF2= NYG2SYJNTE2VTx?= NX;tTG9XfXC{ZXf1cIF1\XNicILvZZBweHSxdHnjJIFv\CClZXzsJIN6[2ynIHHydoV{fCCpZX7ldy=> MX6yOFkxPjF|Nx?=
SK-Mel-28 M{HydmZ2dmO2aX;uJIF{e2G7 NFO3VlcyOCEQvF2= NGmxOJlFVVOR NU[yNGRkfXC{ZXf1cIF1\XNicILvZZBweHSxdHnjJIFv\CClZXzsJIN6[2ynIHHydoV{fCCpZX7ldy=> M4HaZ|I1QTB4MUO3
Mel-RMU MUHGeY5kfGmxbjDhd5NigQ>? M2TUVVExKM7:TR?= NWf3[JY5TE2VTx?= MnXOeZBz\We3bHH0[ZMheHKxYYDvdJRwfGmlIHHu[EBk\WyuIHP5Z4xmKGG{cnXzeEBo\W6ncx?= M2TNV|I1QTB4MUO3
Mel-JD M3PWNWZ2dmO2aX;uJIF{e2G7 MVixNEDPxE1? M{LhemROW09? MX;1dJJm\3WuYYTld{Bxem:jcH;weI91cWNiYX7kJINmdGxiY4njcIUh[XK{ZYP0JIdmdmW| MXGyOFkxPjF|Nx?=
Mel-RM MVLGeY5kfGmxbjDhd5NigQ>? NVjxbplPOTBizszN NGnBV4hFVVOR NV\6Vm1YfXC{ZXf1cIF1\XNicILvZZBweHSxdHnjJIFv\CClZXzsJIN6[2ynIHHydoV{fCCpZX7ldy=> M3vFclI1QTB4MUO3

... Click to View More Cell Line Experimental Data

In vivo Administration of I-BET151 at 30 mg/kg/day significantly inhibits tumor growth of murine MLL-AF9 and human MLL-AF4 leukaemia in mice, and provides marked survival benefit. [1]

Protocol

Kinase Assay:

[1]

+ Expand

Fluorescence anisotropy (FP) ligand displacement assay:

All components are dissolved in buffer of composition 50 mM HEPES pH 7.4, 150 mM NaCl and 0.5 mM CHAPS with final concentrations of BRD 2/3/4 75 nM, fluorescent ligand 5 nM. 10 μL of this reaction mixture is added using a micro multidrop to wells containing 100 nL of various concentrations of I-BET151 or DMSO vehicle (1% final) in Greiner 384 well Black low volume microtitre plate and equilibrated in the dark for 60 minutes at room temperature. Fluorescence anisotropy is read in Envision (lex = 485 nm, lEM = 530 nm; Dichroic = 505 nM).
Cell Research:

[1]

+ Expand
  • Cell lines: MV4;11, MOLM13, NOMO1, RS4;11, HEL, HL60 and K562
  • Concentrations: Dissolved in DMSO, final concentrations ~100 μM
  • Incubation Time: 24, or 72 hours
  • Method:

    Cells are exposed to various concentrations of I-BET151 for 24 or 72 hours in 384-well or 96-well plates. For cell growth inhibition assays, plates are added with CellTiter-Glo reagent using a volume equivalent to the cell culture volume in the wells, shaken for approximately 2 minutes and chemiluminescent signal is read on the Analyst GT or EnVision Plate Reader. For cell proliferation assays, CellTiter-Aqueous One is added to each well and plates are incubated for 4 hours at 37 °C. Absorbance is read at 490 nm on a SpectraMax Gemini reader


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: NOD-SCID mice injected intravenously with MV4;11 cells, and C57BL/6 mice injected intravenously with MLL-AF9 cells
  • Formulation: Dissolved in normal saline containing 5% (v/v) DMSO and 10% (w/v) Kleptose HPB
  • Dosages: ~30 mg/kg/day
  • Administration: Intraperitoneal injection
    (Only for Reference)

Solubility (25°C)

In vitro Ethanol 27 mg/mL (64.99 mM)
DMSO Insoluble
Water Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 415.44
Formula

C23H21N5O3

CAS No. 1300031-49-5
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Epigenetic Reader Domain Signaling Pathway Map

Epigenetic Reader Domain Inhibitors with Unique Features

Tags: buy I-BET151 (GSK1210151A) | I-BET151 (GSK1210151A) supplier | purchase I-BET151 (GSK1210151A) | I-BET151 (GSK1210151A) cost | I-BET151 (GSK1210151A) manufacturer | order I-BET151 (GSK1210151A) | I-BET151 (GSK1210151A) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID